NexImmune’s next act

How differing opinions on pipeline strategy led to NexImmune buyout

Management’s and investors’ different views about what product to develop first was the catalyst for the sale of immuno-oncology play NexImmune Inc. to a new syndicate led by Sol Barer, chairman of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA;

Read the full 376 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE